| scholarly article | Q13442814 |
| P2093 | author name string | Florian Lordick | |
| Yelena Y Janjigian | |||
| P2860 | cites work | Characteristics and clinical outcome of proximal-third gastric cancer | Q77448781 |
| Molecular biology. Cancer's perpetual source? | Q80838334 | ||
| Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization | Q82232659 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| Comparative study on overexpression of HER2/neu and HER3 in gastric cancer | Q84302634 | ||
| HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges | Q84818400 | ||
| Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis | Q86003418 | ||
| Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial | Q87206964 | ||
| Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status | Q87492670 | ||
| Targeting the HGF/MET pathway in gastric cancer | Q88155357 | ||
| Transplacental carcinogenesis by stilbestrol | Q95784569 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Chemotherapy for advanced gastric cancer | Q24236634 | ||
| Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels | Q24299513 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells | Q28294874 | ||
| Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration | Q29547429 | ||
| Wnt activity defines colon cancer stem cells and is regulated by the microenvironment | Q29618024 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors | Q29619686 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers | Q30652890 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics | Q33601653 | ||
| Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q33658636 | ||
| Epidemiology of gastric cancer | Q33788193 | ||
| Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. | Q33925951 | ||
| Targeted inhibition of VEGF receptor 2: an update on ramucirumab | Q34040956 | ||
| A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer | Q34051972 | ||
| Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q34094855 | ||
| Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression | Q34096315 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program | Q48523290 | ||
| Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. | Q50046173 | ||
| CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. | Q50958590 | ||
| Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. | Q51537752 | ||
| HER2 expression in carcinomas of the true cardia (Siewert type II esophagogastric junction carcinoma). | Q51777964 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in Germany. | Q52875534 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
| The cancer stem cell gamble. | Q53642808 | ||
| Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. | Q54218339 | ||
| Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 | ||
| Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. | Q54483761 | ||
| Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 | ||
| Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. | Q54675358 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Cereal fiber intake may reduce risk of gastric adenocarcinomas: The EPIC-EURGAST study | Q57054336 | ||
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer | Q57152489 | ||
| Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations | Q57266547 | ||
| Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations | Q59182691 | ||
| Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated | Q59616698 | ||
| Rising incidence of adenocarcinoma of the esophagus and gastric cardia | Q68199481 | ||
| Gastric precancerous process in a high risk population: cross-sectional studies | Q68852382 | ||
| Precancerous gastric lesions in a population at high risk of stomach cancer | Q70586647 | ||
| Distribution of Abo Blood Groups in Patients with Pernicious Anemia, Gastric Carcinoma and Gastric Carcinoma Associated with Pernicious Anemia | Q72545373 | ||
| Different patterns of recurrence in gastric cancer depending on Lauren's histological type: longitudinal study | Q74713453 | ||
| Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome | Q34205748 | ||
| Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. | Q34303695 | ||
| Helicobacter pylori and gastric carcinogenesis. | Q34311677 | ||
| Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research | Q34346468 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Diet and the risk of gastric cancer: review of epidemiological evidence | Q34580455 | ||
| E-cadherin germline mutations in familial gastric cancer. | Q34746744 | ||
| Genetic screening for hereditary diffuse gastric cancer | Q35089156 | ||
| Suppression of cancer relapse and metastasis by inhibiting cancer stemness | Q35090120 | ||
| Age-specific trends in incidence of noncardia gastric cancer in US adults. | Q35126126 | ||
| Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology | Q35584856 | ||
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity | Q35591349 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma | Q35598804 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer | Q35746639 | ||
| Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer | Q35768487 | ||
| Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma | Q35830806 | ||
| A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets | Q35878807 | ||
| Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). | Q35981433 | ||
| Fruit and vegetables consumption and gastric cancer: a systematic review and meta-analysis of cohort studies | Q36340595 | ||
| Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. | Q36374816 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Her2/neu testing in gastric cancer: evaluating the risk of sampling errors | Q36615782 | ||
| BRCA2 gene mutations in families with aggregations of breast and stomach cancers | Q36646182 | ||
| Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer | Q36778082 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| MET amplification as a potential therapeutic target in gastric cancer. | Q36984821 | ||
| Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. | Q37141350 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies | Q37475411 | ||
| Stem cells and cancer of the stomach and intestine | Q37769649 | ||
| Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population | Q38083585 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Gastric cancer: epidemiology and risk factors. | Q38103683 | ||
| Optimal chemotherapy for advanced gastric cancer: is there a global consensus? | Q38139297 | ||
| HER2 directed therapy for gastric/esophageal cancers | Q38210387 | ||
| Revisiting STAT3 signalling in cancer: new and unexpected biological functions | Q38262473 | ||
| Familial gastric cancer: genetic susceptibility, pathology, and implications for management | Q38339098 | ||
| On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation | Q38391533 | ||
| Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie | Q38416059 | ||
| Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. | Q38420500 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| Global patterns of cardia and non-cardia gastric cancer incidence in 2012. | Q38951159 | ||
| Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. | Q39172509 | ||
| FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. | Q39181047 | ||
| Gastric lesions in familial adenomatosis coli: their incidence and histologic analysis | Q39196345 | ||
| Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models | Q39519148 | ||
| Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. | Q39736030 | ||
| Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic | Q40396835 | ||
| A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group st | Q40556214 | ||
| Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review | Q40901949 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| The Lauren classification highlights the role of epithelial-to-mesenchymal transition in gastric carcinogenesis: an immunohistochemistry study of the STAT3 and adhesion molecules expression. | Q41141108 | ||
| Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond | Q41579926 | ||
| International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus | Q42465120 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
| Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Q43712233 | ||
| Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study | Q44236435 | ||
| Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma | Q44588813 | ||
| Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms | Q44680981 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening | Q44894734 | ||
| Trends in incidence of oesophageal and stomach cancer subtypes in Europe. | Q45117256 | ||
| Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families | Q45243999 | ||
| Lymph node metastasis in early gastric cancer: evaluation of a novel method for measuring submucosal invasion and development of a nodal predicting index | Q45365260 | ||
| Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus | Q45419139 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gastroesophageal cancer | Q61913382 |
| P304 | page(s) | 348-360 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Clinical impact of tumour biology in the management of gastroesophageal cancer | |
| P478 | volume | 13 |
| Q90353138 | A 18FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer |
| Q52727768 | A proteomic landscape of diffuse-type gastric cancer. |
| Q64103643 | A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors |
| Q54465350 | Anti-angiogenesis: disappointment in localised oesophagogastric cancer. |
| Q55356265 | Associations between CA19-9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer. |
| Q50017317 | CXCR4-expressing Mist1+ progenitors in the gastric antrum contribute to gastric cancer development. |
| Q90449717 | Chances, risks and limitations of neoadjuvant therapy in surgical oncology |
| Q90196913 | Chromosomal instability of circulating tumor DNA reflect therapeutic responses in advanced gastric cancer |
| Q94545799 | Clinical and prognostic association of oncogene cadherin 11 in gastric cancer |
| Q54976942 | Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine. |
| Q90753927 | Current applications of molecular testing on body cavity fluids |
| Q47564950 | Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. |
| Q38876434 | Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer |
| Q38656687 | Expression and function of transforming growth factor‑β‑activated protein kinase 1 in gastric cancer |
| Q37534187 | Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling |
| Q57109545 | HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer |
| Q26746253 | HER2 testing in gastric cancer: An update |
| Q64113608 | Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics |
| Q63406942 | Human gastric cancer modelling using organoids |
| Q90306719 | MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells |
| Q57809707 | MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer |
| Q59354957 | Mutations in and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma |
| Q46247676 | NR4A1-induced increase in the sensitivity of a human gastric cancer line to TNFα-mediated apoptosis is associated with the inhibition of JNK/Parkin-dependent mitophagy |
| Q38759129 | New agents on the horizon in gastric cancer |
| Q37545081 | PCAF acts as a gastric cancer suppressor through a novel PCAF-p16-CDK4 axis |
| Q91788788 | Phosphoglucose isomerase gene expression as a prognostic biomarker of gastric cancer |
| Q58720903 | Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer |
| Q52890908 | Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes. |
| Q39061328 | Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. |
| Q88959338 | Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer |
| Q99212159 | Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients |
| Q52568539 | RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. |
| Q89686099 | SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop |
| Q47579309 | Salvage chemotherapy for advanced gastric cancer: more than a false hope? |
| Q38712760 | Silencing of ATP4B of ATPase H+/K+ Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells |
| Q52657273 | The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. |
| Q89867740 | The LINC00365/SCGB2A1 (Mammaglobin B) Axis Down-Regulates NF-κB Signaling and Is Associated with the Progression of Gastric Cancer |
| Q100428137 | The changing face of gastric cancer: epidemiologic trends and advances in novel therapies |
| Q28078788 | The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond |
| Q92484370 | YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling |
| Q53750080 | [Novel pharmaceutical treatment approaches for gastric cancer]. |
Search more.